Clovis Oncology Acquires Rights to FAP-Targeted Radiopharmaceutical Program from 3B Pharmaceuticals
Clovis Oncology has entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH (3BP), a private German biotechnology company developing targeted…
Read More...
Read More...
